Show
Sort by
-
- Journal Article
- A1
- open access
Recent advancements in 18F-labeled PSMA targeting PET radiopharmaceuticals
-
- Journal Article
- A1
- open access
Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours
-
- Journal Article
- A1
- open access
The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy : a review of the lessons learnt so far
-
- Journal Article
- A1
- open access
Gold nanoparticles meet medical radionuclides
-
2-[18F]FELP, a novel LAT1-specific PET tracer, for the discrimination between glioblastoma, radiation necrosis and inflammation
-
Validation of hepatobiliary transport PET imaging in liver function assessment : evaluation of 3β-[18F]FCA in mouse models of liver disease
-
Synthesis, in vitro and in vivo small-animal SPECT evaluation of novel technetium labeled bile acid analogues to study (altered) hepatic transporter function
-
18F-fluoromethylcholine (FCho), 18F-fluoroethyltyrosine (FET), and 18F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study
-
In vivo imaging of Zr-89-labeled poly(2-ethyl-2-oxazoline)s and poly(ethylene glycol)s
-
The influence of mass of [11C]-laniquidar and [11C]-N-desmethylloperamide on P-glycoprotein blockage at the blood-brain barrier